BioInvent Completes the Planned Dose-Escalation in Phase 1/2a trial of BI-1808 in Advanced Malignancies

LUND, SWEDEN / ACCESSWIRE / September 6, 2022 / BioInvent International (STO:BINV)BI-1808 shown to be safe and well tolerated with no serious adverse events observedGiven the positive safety and tolerability profile, higher doses will be …